Skip to Content
Merck
  • Cell-free microfluidic determination of P-glycoprotein interactions with substrates and inhibitors.

Cell-free microfluidic determination of P-glycoprotein interactions with substrates and inhibitors.

Pharmaceutical research (2014-06-15)
Klaus Eyer, Michael Herger, Stefanie D Krämer, Petra S Dittrich
ABSTRACT

The membrane protein P-glycoprotein (P-gp) plays key roles in the oral bioavailability of drugs, their blood brain barrier passage as well as in multidrug resistance. For new drug candidates it is mandatory to study their interaction with P-gp, according to FDA and EMA regulations. The vast majority of these tests are performed using confluent cell layers of P-gp overexpressing cell lines that render these tests laborious. In this study, we introduce a cell-free microfluidic assay for the rapid testing of drug- P-gp interactions. Cell-derived vesicles are prepared from MDCKII-MDR1 overexpressing cells and immobilized on the surface of a planar microfluidic device. The drug is delivered continuously to the vesicles and calcein accumulation is monitored by means of a fluorescence assay and total internal reflection fluorescence (TIRF) microscopy. Only small amounts of compounds (~10 μl) are required in concentrations of 5, 25 and 50 μM for a test that provides within 5 min information on the apparent dissociation constant of the drug and P-gp. We tested 10 drugs on-chip, 9 of which are inhibitors or substrates of P-glycoprotein and one negative control. We benchmarked the measured apparent dissociation constants against an alternative assay on a plate reader and reference data from FDA. These comparisons revealed good correlations between the logarithmic apparent dissociation constants (R(2) = 0.95 with ATPase assay, R(2) = 0.93 with FDA data) and show the reliability of the rapid on-chip test. The herein presented assay has an excellent screening window factor (Z'-factor) of 0.8, and is suitable for high-throughput testing.

MATERIALS
Product Number
Brand
Product Description

Supelco
Loperamide hydrochloride, VETRANAL®, analytical standard
USP
Erythromycin, United States Pharmacopeia (USP) Reference Standard
Supelco
Erythromycin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Trizma® base, ≥99.0% (T)
Sigma-Aldrich
Erythromycin, tested according to Ph. Eur.
Erythromycin, for microbiological assay, European Pharmacopoeia (EP) Reference Standard
Ritonavir, European Pharmacopoeia (EP) Reference Standard
Loperamide hydrochloride, European Pharmacopoeia (EP) Reference Standard
Supelco
Loperamide hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Trizma® base, BioUltra, for molecular biology, ≥99.8% (T)
Sigma-Aldrich
Tris(hydroxymethyl)aminomethane, ACS reagent, ≥99.8%
Sigma-Aldrich
Erythromycin standard solution, 1 mg/mL in H2O
Sigma-Aldrich
Loperamide hydrochloride
Sigma-Aldrich
Erythromycin, BioReagent, suitable for cell culture
Sigma-Aldrich
Trizma® base, BioXtra, pH 10.5-12.0 (1 M in H2O), ≥99.9% (titration)
Sigma-Aldrich
Erythromycin, potency: ≥850 μg per mg
Sigma-Aldrich
Erythromycin, meets USP testing specifications
Sigma-Aldrich
Trizma® base, ≥99.9% (titration), crystalline
Sigma-Aldrich
Tromethamine, meets USP testing specifications
Sigma-Aldrich
Ritonavir, ≥98% (HPLC)
Sigma-Aldrich
Calcein-AM, Small Package (20 X 50 μg ), ≥95.0% (HPLC)
Supelco
Trizma® base, reference material for titrimetry, certified by BAM, >99.5%
USP
Tromethamine, United States Pharmacopeia (USP) Reference Standard
Supelco
Tromethamine, pharmaceutical secondary standard, certified reference material
Ergotamine tartrate, European Pharmacopoeia (EP) Reference Standard
Trometamol, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Trizma® base, anhydrous, free-flowing, Redi-Dri, ≥99.9%
USP
Loperamide hydrochloride, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Ergotamine D-tartrate, ≥97.0% (calc. based on dry substance, NT)
Sigma-Aldrich
Trizma® base, Primary Standard and Buffer, ≥99.9% (titration), crystalline